Oct 12 (Reuters) - BiVictriX Therapeutics PLC:
* EXTENDED SURVIVAL RATES REPORTED WITH BVX001 IN A PRE-CLINICAL MODEL OF ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11 GBX | 0.00% | -4.35% | +4.76% |
17/04 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
17/04 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Oct 12 (Reuters) - BiVictriX Therapeutics PLC:
* EXTENDED SURVIVAL RATES REPORTED WITH BVX001 IN A PRE-CLINICAL MODEL OF ACUTE MYELOID LEUKAEMIA Source text for Eikon: Further company coverage:
1st Jan change | Capi. | |
---|---|---|
+4.76% | 11.54M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.60% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |